Publication: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis
1
Issued Date
2000-05-10
Resource Type
ISSN
03065251
Other identifier(s)
2-s2.0-0034012806
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
British Journal of Clinical Pharmacology. Vol.49, No.5 (2000), 445-452
Suggested Citation
B. J. Angus, M. D. Smith, Y. Suputtamongkol, H. Mattie, A. L. Walsh, V. Wuthiekanun, W. Chaowagul, N. J. White Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology. Vol.49, No.5 (2000), 445-452. doi:10.1046/j.1365-2125.2000.00179.x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/26245
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis
Abstract
Aims. Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta-lactam antibiotics for serious Gram-negative infections. Severe melioidosis (Burkholderia pseudomallei infection) carries a mortality of 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis. Methods. Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg-18 hourly by bolus injection or 4 mg kg-1h-1by constant infusion following a 12 mg kg-1priming dose to perform estimation of pharmacokinetic and pharmacodynamic parameters. Results. Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC90of B. pseudomallei was 2 mg l-1, giving a target concentration C(T), of 8 mg l-1. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half-lives of ceftazidime were 0.468 (0.241-0.573) 1 kg-1, 0.058 (0.005-0.159) 1 kg-1h-1and 7.74 (1.95-44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (r = 0.71; P < 0.001) and there was no evidence of significant nonrenal clearance. Conclusions. Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure which is common in these patients is Clearance = k* creatinine clearance where k = 0.072. Calculation of a loading dose gives median (range) values of loading dose, D(L) of 3.7 mg kg-1(1.9-4.6) and infusion rate I = 0.46 mg kg h-1(0.04-1.3) (which equals 14.8 mg kg-1day-1). A nomogram for adjustment in renal failure is given.